Hims & Hers Q2 2026: Revenue Jumps 38% as Outlook Rises on AI-Driven Expansion
Hims & Hers Health reported Q2 2026 revenue of $753.2 million, up 38% year over year, with about 2.89 million subscribers; net loss was $86.3 million, while Adjusted EBITDA was $60.3 million and free cash flow was −$68.2 million. The company raised full-year 2026 guidance to revenue of $3.1–$3.3 billion and Adjusted EBITDA of $275–$325 million, aided by AI-driven efficiencies and rapid international expansion (including the June closing of Eucalyptus), with longer-term targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA by 2030.










